diamox 500 mg price lopressor 375 mg zovirax 400 precio cymbalta 500 naprosyn 750 adalat hindi serial 2015 cytotec 400 mg tetracycline 1000 mobic zc 25 tinidazole (fasigyn 500) suhagra 100 how to use kurtlar vadisi pusu 181 yaygara comprar zovirax comprimido precio nolvadex mexico necesita receta propecia ginseng 1000 mg uso del neurontin 300 mg trental 100 mg 5 ampul femara 25 precio donde comprar valtrex furosemide 10 mg side effects pastillas aldactone keppra xr 500 citalopram 10 mg vademecum isoptin 80 mg tb 625 mg promethazine comprar tadapox kamagra gold 100 erfahrung accutane 80 mg side effects 5 mg accutane per day que precio tiene el zovirax aricept 5 mg 14 film tablet nom generique de l'aspirine que precio tienen las pastillas vermox voltaren sr 100 liposafe – pílula para perder peso de forma natural aldactone 100 espironolactona rocaltrol 025 para que sirve prednisona para perros efectos secundarios efectos secundarios de las pastillas minocin blopress plus 16 mg para que sirve efectos sildenafil felodipine plendil 5 mg comprar alli 120 capsulas tamoxifen citrate 20 mgml x 60ml avapro irbesartan 300 mg natural prometrium during pregnancy natural progesterone pills prometrium 75 mg methotrexate weekly efectos secundarios de las pastillas minocin topamax 400 mg side effects pariet 5 mg aciclovir 500 mg iv 10 coupon for valtrex cozaar 50 mg farmatodo comprar hoodia p57 en españa avodart 5 mg side effects renagel 800 mg precio en mexico efectos secundarios de amoxicillin 500mg precio de las pastillas nitrofurantoina malegra pro 100 mg zithromax 40 mg ml hinta harga blopress 8 mg nimotop 30 para que sirve trental 600 mg comprimidos suhagra 100 how to use desyrel dividose 150 mg comprar hoodia gordonii en argentina renagel 800 mg precio en mexico tadalafil black 800 mg para que sirven las pastillas coreg sildenafil citrate tablets caverta 100 6 mg risperdal femara 75 mg follicles remeron 30 mg precio mobic ampolla 15 mg motrin 500 dosage actonel tabletas 35 mg rumalaya comprar geof cefixime 100 suspension precio xeloda 500 mg hydrea professional body brush with natural bristles medium strength motrin 400 mg para que sirve jl arjuna utara no 50 furosemide 80 mg iv push precio corega tabs prednisolone mylan 20 mg floxin 400 mg 100 g of calcium carbonate is heated and produced 56 g of calcium oxide clomid precio en farmacia chile comprar amoxicillin zovirax 400 precio 800 mg dramamine efectos del motilium en bebes duphalac 10g 15ml acyclovir 1000 mg iv hydrochlorothiazide 50 mg picture natural substitute for effexor natural aspirin naprosyn 750 effexor 40 mg adalat pastillas propranolol 20 mg nombre comercial amitriptyline tab 25mg zithromax 600 mg suspension allegra precio natural alternatives to vioxx celebrex donde puedo comprar metformin 2mg zanaflex high 300 mg zyban viagra super active comprar aldactone 50 mg bula trental 100 mg 5 ampul preço pariet 20mg BioLife Solutions Commences Build-Out of Second GMP Production Suite and Corporate Office Expansion

BioLife Solutions Commences Build-Out of Second GMP Production Suite and Corporate Office Expansion


Demand for HypoThermosol® and CryoStor®, and New Contract Manufacturing Agreement Driving Growth and Creation of New Jobs       03/05 06:00 AM


BOTHELL, Wash., March 5, 2012 /PRNewswire/ — BioLife Solutions, Inc. (BLFS:$0.08,00$0.00,000.00%) , a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, today announced that it has executed an amendment to its current commercial lease to double the square footage of its existing facilities.  The additional space will be dedicated to the build-out of an additional GMP manufacturing clean room suite and space for additional team members, whose jobs are being created by increasing demand for the Company’s biopreservation media products and also a high value contract manufacturing agreement that was executed in late 2011.  BioLife’s operations are located in Monte Villa Farms, a Bothell biotech and data center campus.
(Logo:  http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)
Mike Rice, Chief Executive Officer, commented on the outlook for BioLife by stating, “We’re very pleased to see demand for HypoThermosol and CryoStor continuing to increase.  Our best-in-class proprietary products are now recognized by key opinion leaders and a growing customer base in our strategic market segments of regenerative medicine, biobanking, and drug discovery.  This growth, along with a new contract manufacturing customer we acquired late in 2011, will enable BioLife to create up to 10 additional jobs in manufacturing, quality assurance, sales, and marketing. We estimate ending 2012 with 25 team members and having significantly increased revenue over 2011.”
Shipments to BioLife’s new contract manufacturing customer are anticipated to start in the second quarter of 2012.
Daphne Taylor, Chief Financial Officer remarked on the terms of the lease amendment by stating, “In addition to considering an option to expand within our current campus, we evaluated a number of suitable local properties. In the end, we received a very competitive and supportive offer from our landlord and chose to expand our operations in our existing facilities. We look forward to increasing our manufacturing capacity and the size of our team to meet the growing demand for our products and services.”
About BioLife Solutions (BLFS:$0.08,00$0.00,000.00%)
BioLife Solutions (BLFS:$0.08,00$0.00,000.00%) develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.  The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife’s products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death.  BioLife’s enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions (BLFS:$0.08,00$0.00,000.00%) ‘ actual results to differ materially are discussed in the Company’s recent filings with the Securities and Exchange Commission.  BioLife Solutions (BLFS:$0.08,00$0.00,000.00%) disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. 
Media Relations:Investor Relations:
Len HallMatt Clawson
Allen & Caron IncAllen & Caron Inc
(949) 474-4300(949) 474-4300
len@allencaron.com matt@allencaron.com 

SOURCE BioLife Solutions, Inc. (BLFS:$0.08,00$0.00,000.00%)



Welcome to Investor Stemcell! New to the site? Take a minute and Sign Up Today!